Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Praluent Launch Brings Clinical Practice Challenges

Executive Summary

Despite enthusiasm about PCSK9 class, the prescribing community will have to wrestle with patient-selection criteria, uncertainty about very low LDL levels and a lack of outcomes data for Sanofi and Regeneron’s alirocumab.

Advertisement

Related Content

Sanofi's Praluent And Amgen's Repatha Now Set For Battle In Europe, US
CVS Health Seeks Return To LDL Treatment Targets To Control PCSK9s
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Praluent Coverage: Being First May Not Matter As Payers Await Repatha
Reading The Praluent Tea Leaves Ahead Of Repatha's Approval
Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel